首页> 外文期刊>Expert opinion on therapeutic targets >Multifaceted targeting in cancer: the recent cell death players meet the usual oncogene suspects.
【24h】

Multifaceted targeting in cancer: the recent cell death players meet the usual oncogene suspects.

机译:癌症的多方面靶向:最近的细胞死亡参与者遇到了常见的致癌基因嫌疑人。

获取原文
获取原文并翻译 | 示例
           

摘要

Recent complicated advances towards the blueprinting of the altered molecular networks that lie behind cancer development have paved the way for targeted therapy in cancer. This directed a significant part of the research community to the development of specialized targeted agents, many of which are already available or in clinical trials. The prospect of patient-tailored therapeutic strategies, although very close to becoming a reality also raises the level of complexity of the therapeutic approach. This review summarizes the functions, in vivo expression patterns and aberrations of factors presently targeted or representing potential targets by therapeutic agents, focusing on those implicated in death receptor-induced apoptosis. The authors overview the regulation of these factors and death receptor-induced apoptosis by classical oncogenes (e.g., RAS, MYC, HER2) and their effectors/regulators, most of which are also being targeted. In addition, the importance of orthologic systemic approaches in future patient-tailored therapies are discussed.
机译:癌症发展背后改变的分子网络蓝图的最新复杂进展为癌症的靶向治疗铺平了道路。这将研究社区的重要部分引向了专门靶向药物的开发,其中许多药物已经可用或正在临床试验中。量身定制的治疗策略的前景,尽管非常接近成为现实,但也提高了治疗方法的复杂性。这篇综述总结了目前由治疗剂靶向或代表潜在靶标的因子的功能,体内表达模式和畸变,重点是与死亡受体诱导的细胞凋亡有关的因子。作者概述了经典致癌基因(例如RAS,MYC,HER2)及其效应子/调节子对这些因子和死亡受体诱导的细胞凋亡的调节,其中大多数也是靶向的。此外,还讨论了矫正系统方法在未来针对患者的治疗中的重要性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号